Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memory Pharmaceuticals

Criteria

Inclusion Criteria:

• Diagnosis of probable or possible Alzheimer's disease

• MMSE score between 16 and 26 points

• Modified Hachinski Ischemia Score of less than or equal to 4

• Capable of performing cognitive tests and other procedures specified in protocol

Exclusion Criteria:

• Head trauma associated with cognitive impairment

• Evidence of significant neurological disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, CNS tumor, progressive supranuclear palsy, seizure disorder, etc.

• Received AChE inhibitor therapy (e.g., rivastigmine, tacrine or galantamine) or NDMA-receptor antagonist, memantine, within 30 days or donepezil within 40 days of randomization

• Received any investigational drug within 2 months of randomization or treatment with other nicotinic receptor agonists within 3 months of screening